These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Author: Chertow GM, Dillon MA, Amin N, Burke SK.
    Journal: J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533.
    Abstract:
    OBJECTIVE: To determine the effects of sevelamer hydrochloride on serum phosphorus, calcium, calcium x phosphate product, and parathyroid hormone (PTH) in patients treated with and without vitamin D metabolites and calcium supplementation. DESIGN: Long-term, open-label clinical trial. SETTING: Hemodialysis units. PATIENTS: One hundred ninety-two adult patients with end-stage renal disease on hemodialysis. INTERVENTION: An extended treatment period of sevelamer hydrochloride, preceded and followed by phosphate binder washout periods. MAIN OUTCOME MEASURES: Treatment-related changes in serum phosphorus, calcium, calcium x phosphate product, and PTH. RESULTS: Subjects treated with sevelamer alone, sevelamer with vitamin D metabolites (with or without calcium), and sevelamer with calcium without vitamin D experienced significant reductions in mean serum phosphorus (range, 2.1 to -2.9 mg/dL) and the calcium x phosphate product (range, -16.3 to -23.4 mg2/dL2). The mean serum calcium concentration increased in all subgroups except those treated with sevelamer alone (range, +0.3 to +0.5 mg/dL). In contrast, only subjects treated concurrently with vitamin D metabolites experienced a reduction in PTH. Subjects treated with sevelamer alone or sevelamer with calcium without vitamin D experienced an increase in PTH with treatment. CONCLUSION: Sevelamer hydrochloride is a safe and effective phosphate binder in hemodialysis patients. Sevelamer should be used in combination with vitamin D metabolites to jointly control hyperphosphatemia and hyperparathyroidism. Randomized clinical trials will be required to determine the optimal management strategies for metabolic bone disease in end-stage renal disease, as well as less advanced stages of chronic renal insufficiency.
    [Abstract] [Full Text] [Related] [New Search]